GE Healthcare and Insightec®, a global medical innovator of incisionless surgery, announced US and EU regulatory approval for Exablate NeuroTM compatible with the SIGNATM Premier MR system. Exablate NeuroTM is a focused ultrasound platform for treating the brain with no surgical incisions. MR imaging provides a comprehensive anatomical survey of the treatment area, patient-specific planning and real-time thermal monitoring throughout the treatment.
Exablate NeuroTM has FDA approval for the treatment of medication-refractory essential tremor and tremor-dominant Parkinson’s disease and CE marked for the treatment of essential tremor, tremor dominant Parkinson’s Disease-Unilateral and neuropathic pain.
“We’re excited to continue expanding MR-guided focused ultrasound offerings with Insightec®,” said Baldev Ahluwalia, General Manager, MR Beyond Segment at GE Healthcare.
